PPARG and prostate adenocarcinoma: Azelaoyl-PAF, an OxPL, stimulates PAF receptor (PAFR) and behaves as an agonist of PPAR-γ, a common receptor on normal tissues and prostate adenocarcinoma cell lines, as well as a reported tumor growth inhibitor.